Noah Friedman

Expert in AI x Biology

Jackson, Wyoming, United States

About

Experience

  • Founder at Tetonic AI
    Aug 2025 - Present · 1 yr

  • Natera ()
    • AI Strategy Consultant
      Mar 2024 - Present · 2 yrs 5 mos

    • Senior Bioinformatics Data Scientist
      Oct 2022 - Mar 2024 · 1 yr 6 mos

  • AI Lead at Advanced Research Projects Agency for Health (ARPA-H)
    Mar 2024 - Feb 2025 · 1 yr

    Leading a team developing AI tools, strategy and policy for ARPA-H.

  • Senior Cancer Genomics Analyst at C2i Genomics
    Oct 2020 - Jul 2022 · 1 yr 10 mos

    • Responsible for development of pipeline for copy number informed detection of tumor material in circulating tumor DNA. Oversaw development from initial proof of concept to performance validation to integration into product pipeline • Implemented algorithm to characterized and detect tumor signal as determined by genomic features including allele specific copy number, tumor clonality, mutation copy number and somatic mutations • Developed algorithms for robust, replicable and fast performance in cloud environment: scripting, automated evaluation, high performance computing (aws) configuration • Prepared reports and led research initiatives to tailor product to integrate signal across various tumor derived signal classes, and characterized the difference in these analytes between tumor and normal data • Examined and fine-tuned algorithm performance across a diverse set of cancers representing distinct cancer types, genomic profiles and cancer tumor fractions • Used liquid biopsy data to track and categorize the evolution of tumors over treatment course without the need for a tissue biopsy

  • Computational Biologist at Memorial Sloan Kettering Cancer Center
    Jan 2018 - Oct 2020 · 2 yrs 10 mos

    • First author publication drafted on evolutionary consequences of hypermutation in human cancer: disambiguating driver and passenger mutations, understanding positive and negative selection in hypermutated cancer, understanding temporal development of hypermutated cancer, developing a framework to understand evolutionary imperatives of hypermutated cancer • Genomics research on evolution of cancer centered around analysis of targeted sequence cohort of 50k patients • Analyses of the contribution of environmental and endogenous mutational processes to cancer development through mutational signatures, copy number changes, phylogenetic analysis • Analyses of intra-tumoral heterogeneity, mechanisms of gene inactivation, disambiguation of cancer driver and passenger mutations, mutational event validations, copy number changes in human cancer and selective landscape of human malignancies • Contributions to published papers on BRCA dysfunction in human cancer, comparisons between exome and targeted panel sequencing, compound mutagenesis in cancer, landscape of microsatellite instability in human cancer • Extensive work with cancer data pipelines, analytical methods and visualization for publication quality figures